Quote | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
Last: | $5.60 |
---|---|
Change Percent: | 0.0% |
Open: | $5.72 |
Close: | $5.60 |
High: | $6.09 |
Low: | $5.56 |
Volume: | 452,077 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
2024-06-27 04:13:22 ET Summary ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcom...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
Message Board Posts | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
Subject | By | Source | When |
---|---|---|---|
Right... !! is probably more like it. Absolute | biocqr | investorshub | 11/23/2020 3:40:34 PM |
Didnt mean ?? Lol. Whoops. | sgunderbarth | investorshub | 11/23/2020 2:55:38 PM |
?? | biocqr | investorshub | 11/17/2020 11:09:21 PM |
?? | sgunderbarth | investorshub | 11/17/2020 7:33:16 PM |
$1.5mil trade x $43 | sgunderbarth | investorshub | 08/12/2020 4:47:36 PM |
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...
2024-05-10 08:30:07 ET H.C. Wainwright analyst issues BUY recommendation for ALXO on May 10, 2024 06:40AM ET. The previous analyst recommendation was Buy. ALXO was trading at $16.95 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...